A detailed history of Keybank National Association transactions in Genmab A/S stock. As of the latest transaction made, Keybank National Association holds 28,355 shares of GMAB stock, worth $596,022. This represents 0.0% of its overall portfolio holdings.

Number of Shares
28,355
Previous 30,547 7.18%
Holding current value
$596,022
Previous $767,000 9.91%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 31, 2024

SELL
$23.84 - $28.48 $52,257 - $62,428
-2,192 Reduced 7.18%
28,355 $691,000
Q2 2024

Jul 31, 2024

SELL
$25.13 - $30.27 $26,160 - $31,511
-1,041 Reduced 3.3%
30,547 $767,000
Q1 2024

May 14, 2024

SELL
$26.43 - $32.77 $15,831 - $19,629
-599 Reduced 1.86%
31,588 $944,000
Q4 2023

Feb 13, 2024

SELL
$27.94 - $35.44 $15,227 - $19,314
-545 Reduced 1.67%
32,187 $1.02 Million
Q3 2023

Nov 08, 2023

BUY
$35.27 - $42.24 $1.15 Million - $1.38 Million
32,732 New
32,732 $1.15 Million

Others Institutions Holding GMAB

About GENMAB A/S


  • Ticker GMAB
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 658,292,992
  • Market Cap $13.8B
  • Description
  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...
More about GMAB
Track This Portfolio

Track Keybank National Association Portfolio

Follow Keybank National Association and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Keybank National Association, based on Form 13F filings with the SEC.

News

Stay updated on Keybank National Association with notifications on news.